Due to the promising role of immunotherapy in HER2+ BC, the recent introduction of immune checkpoint inhibitors and other immunotherapeutic agents capable of unleashing an anti-tumoral immune response opens new possibilities for therapeutic combinations in this setting. The gene discussed is ERBB2; the disease is breast cancer.